DPP-4 inhibitors
Dipeptidyl Peptidase 4 Inhibitors and Inflammation: Dpp 4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
12
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
11
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
9
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
10
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
10
Alogliptin: a new addition to the class of DPP-4 inhibitors
10
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
9
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
11
Synthesis of new DPP 4 inhibitors based on a novel tricyclic scaffold
7
Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins
16
Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
5
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
13
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
9
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
9
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus
7
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
19
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
10
Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines
8
Review Article Combined use of dipeptidyl peptidase-4 inhibitors and metformin reduces blood sugar level and improves pancreatic islet β cell function in the treatment of type 2 diabetes mellitus: a meta-analysis
9
Original Article Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis
10